Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Revenue (2016 - 2026)

Pharma-Bio Serv's Revenue history spans 16 years, with the latest figure at $2.3 million for Q1 2026.

  • For Q1 2026, Revenue fell 7.14% year-over-year to $2.3 million; the TTM value through Jan 2026 reached $8.8 million, down 8.08%, while the annual FY2025 figure was $9.0 million, 5.34% down from the prior year.
  • Revenue reached $2.3 million in Q1 2026 per PBSV's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $5.0 million in Q1 2022 to a low of $2.0 million in Q3 2025.
  • Average Revenue over 5 years is $3.4 million, with a median of $2.5 million recorded in 2025.
  • Peak YoY movement for Revenue: increased 11.83% in 2022, then tumbled 47.9% in 2024.
  • A 5-year view of Revenue shows it stood at $4.6 million in 2022, then decreased by 22.42% to $3.6 million in 2023, then crashed by 35.15% to $2.3 million in 2024, then dropped by 7.87% to $2.1 million in 2025, then increased by 6.76% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Revenue are $2.3 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025).